AKBA · Akebia Therapeutics, Inc.
AI read · Bad for AKBA
The AI's read
The new loan gives Akebia some extra cash and replaces old borrowing, but the filing does not say how the old loan’s cost compares. The new loan charges at least 11.5% interest and can reach 15%. The loan is backed by nearly all company assets. Warrants can add shares, early repayment can carry fees, and lenders may reject the extra loan tranches. These costs make the deal unfavorable despite the added cash.